Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma

Journal of Veterinary Internal Medicine

Volumn 18, Issue 2, 2004, Pages 209-213

  Sorenmo, Karin U ^a,c   Baez, Jennifer L ^a   Clifford, Craig A ^a,b   Mauldin, Elizabeth ^a   Overley, Beth ^a   Skorupski, Katherine ^a   Bachman, Roxanne ^a   Samluk, Marissa ^a   Shofer, Frances ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chemotherapy; Dogs; Dose intensity; Malignant endothelioma

Indexed keywords

DOXORUBICIN;

ANGIOSARCOMA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARDIOMYOPATHY; CLINICAL PRACTICE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOG; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; STANDARD; SURVIVAL TIME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOG DISEASES; DOGS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMANGIOSARCOMA; INFUSIONS, INTRAVENOUS; MALE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

CANIS FAMILIARIS;

EID: 1642330300     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2004)18<209:EATOAD>2.0.CO;2     Document Type: Article

References (25)

1. Pearson GR, Head KW. Malignant haemangioendothelioma (angiosarcoma) in the dog. J Small Anim Pract 1976;17:737-745.
2. Moulton JE. Tumors in Domestic Animals, 2nd ed. Berkeley, CA: University of California Press; 1978:35-36.
3. Oksanen A. Hemangiosarcoma in dogs. J Comp Pathol 1978;88: 585-595.
4. Prymak C, McKee LJ, Goldschmidt MH, et al. Epidemiologic, clinical, pathologic, and prognostic characteristics of splenic hemangiosarcoma and splenic hematoma in dogs: 217 cases (1985). J Am Vet Med Assoc 1988;193:706-712.
5. Aronsohn M. Cardiac hemangiosarcoma in the dog: A review of 38 cases. J Am Vet Med Assoc 1985;187:922-926.
6. Johnson KA, Powers BE, Withrow SJ, et al. Splenomegaly in dogs: Predictors of neoplasia and survival after splenectomy. J Vet Intern Med. 1989;3:160-166.
7. Wood CA, Moore AS, Gliatto JG, et al. Prognosis for dogs with stage I and II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991-1993). J Am Anim Hosp Assoc 1998;34:417-421.
8. Brown NO, Patnaik AK, MacEwen EG. Canine hemangiosarcoma: Retrospective analysis of 104 cases. J Am Vet Med Assoc 1985; 186:56-58.
9. Hammer AS, Couto GC, Filppi J, et al. Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma. J Vet Intern Med 1991;5:160-166.
10. Sorenmo KU, Jeglum KA, Helfand SC. Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide. J Vet Intern Med 1993;7:370-376.
11. Ogilvie GK, Powers BE, Mallinckrodt CH, Withrow SJ. Surgery and doxorubicin in dogs with hemangiosarcoma. J Vet Intern Med 1996;10:379-384.
12. Korn EL, Simon R. Using the tolerable-dose diagram in the design of phase 1 combination chemotherapy trials. J Clin Oncol 1993; 11:794-801.
13. Frei E, Elias A, Wheeler C, et al. The relationship between high-dose treatment and combination chemotherapy: The concept of summation dose intensity. Clin Cancer Res 1998;4:2027-2037.
14. DeVita VT. The relationship between tumor mass and resistance to treatment of cancer. Cancer 1983;51:1209-1220.
15. Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: Implications for systemic therapy. Cancer Res 1984;44: 3643-3653.
16. Goldie JH. Scientific basis for adjuvant and primary chemotherapy. Semin Oncol 1987;14:1-7.
17. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia, PA: JB Lippincott Co; 1988:121-141.
18. Berg J, Weinstein MJ, Springfield DS, et al. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med 1995;206(10):1555-1560.
19. Madewell BR, Leighton RL, Theilen GH. Amputation and doxorubicin for treatment of canine and feline osteogenic sarcoma. Eur J Cancer 1978;14:287-293.
20. Smith AN. Hemangiosarcoma in dogs and cats. In: Kitchell BE, ed. The Veterinary Clinics of North America, Small Animal Practice; Advances in Medical Oncology. Philadelphia, PA: WB Saunders; 2003:533-552.
21. Mauldin GE, Fox PR, Patnaik AK, et al. Doxorubicin-induced cardiotoxicosis. J Vet Intern Med 1992;6:82-87.
22. Ward H, Fox LE, Calderwood-Mays MB, et al. Cutaneous hemangiosarcoma in 25 dogs: A retrospective study. J Vet Intern Med 1994;8:345-348.
23. Calfee ET, Dernell WS, Withrow SJ, et al. Chemotherapy interval as a predictor of outcome in canine osteosarcoma treated with doxorubicin following amputation. Proceedings of the Veterinary Cancer Society 22nd Annual Conference, New York, NY, September 12-15, 2002:2.
24. Scotto KW, Bertino JR. Chemotherapy susceptibility and resistance. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA, eds. The Molecular Basis of Cancer. Philadelphia, PA: WB Saunders; 1995:387-400.
25. McVie JG. Drug disposition and pharmacology. In: Fox BW, Fox M, eds. Antitumor Drug Resistance. New York, NY: Springer-Verlag; 1984:39-66.